Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the role of patients' response expectations for nocebo side effects, quality of life and adherence during adjuvant endocrine treatment (AET). Furthermore, this study analyses the effects of a structured treatment information on patients' satisfaction with information, response expectations, knowledge and adherence.
The majority of breast cancer patients discontinues today's standard adjuvant treatment (endocrine therapy) due to side effects and reduced quality of life. Thereby, most side effects are unspecific, suggesting a role of psychological factors as patients´ expectations (nocebo effects). Moreover, patients are not informed sufficiently about their treatment.
Using a longitudinal design, the nature and onset of adverse side effects and their association to treatment related expectations are investigated. Postoperative patients with hormone receptor-positive breast cancer are assessed before the start of adjuvant treatment. All patients receive standardized, additional information about endocrine therapy. Expectations about side effects, knowledge and satisfaction with the enhanced information are assessed before and after informing patients. Side effects, quality of life and adherence are measured three months, two and five years after start of medication intake.
It will be analyzed if patients' response expectations predict side effects and quality of life during medication intake to provide insights into pathways of clinical nocebo effects. Further, this study examines the effects of a structured treatment information on patients' satisfaction with information, response expectations, knowledge and adherence. The study findings promise significant advances in the clinical nocebo research with strong implications for clinical and research practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enhanced information about endocrine therapy | Behavioral | Enhanced information about endocrine therapy, extending clinical routine information |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Side Effects | General Assessment of Side Effects (GASE) | up to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with breast module (QLQ-BR23) | up to 5 years |
| Adherence | Medication Adherence Report Scale (MARS-D); Adherence with endocrine treatment; reasons for non-adherence |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Primary care clinic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yvonne Nestoriuc, Prof. Dr. | Universitätsklinikum Hamburg-Eppendorf | Principal Investigator |
| Winfried Rief, Prof. Dr. | Philipps University Marburg | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Philipps University Marburg Medical Center | Marburg | Hesse | 35032 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29330625 | Derived | Pan Y, Heisig SR, von Blanckenburg P, Albert US, Hadji P, Rief W, Nestoriuc Y. Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study. Breast Cancer Res Treat. 2018 Apr;168(3):667-677. doi: 10.1007/s10549-017-4637-2. Epub 2018 Jan 12. | |
| 27551051 |
| Label | URL |
|---|---|
| Homepage of the research unit (FOR 1328): Expectation and conditioning as basic processes of the placebo and nocebo response: From neurobiology to clinical applications | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| up to 5 years |
| Knowledge | Patients' knowledge of hormone receptor status of their tumor | up to 5 years |
| Satisfaction with Information | Satisfaction with Information about Medicines Scale, (SIMS-D) | Baseline |
| Expectations | General Assessment of Side Effects Scale - Expectations Module | Baseline |
| Coping with Side Effects | General Assessment of Side Effects Scale -Coping Module | Follow-up (3 months, 2 years, 5 years) |
| Nestoriuc Y, von Blanckenburg P, Schuricht F, Barsky AJ, Hadji P, Albert US, Rief W. Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Ann Oncol. 2016 Oct;27(10):1909-15. doi: 10.1093/annonc/mdw266. Epub 2016 Aug 22. |
| D017437 |
| Skin and Connective Tissue Diseases |